Key facts
- It has raised $132.5M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($83.5M) in Mar 2023.
- 2 institutional filers report fund marks on LENZ Therapeutics across 9 filings.
- LENZ Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Mar 2023 ($83.5M sold to 27 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for LENZ Therapeutics
Create free account
No card required
Funding rounds
3 roundsMar 2023Later Stage VC (Series B)$83.5M▮
Nov 2022Later Stage VC (Series A)$49.0M▮
About LENZ Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
LENZ Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in LENZ Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
2 filers · latest May 20262 SEC-registered funds reported 9 fair-value marks on LENZ Therapeutics between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.